cancel

FORMULARZ ZGŁOSZENIOWY


LIST OF RESEARCH


  • add_boxGout
    Study description:

    Phase III study to evaluate the efficacy and safety of tigulixostat in gout patients with hyperuricemia.

    The main criteria that the patient must meet:
    • • age from 18 to 85 years,
    • • patients with hyperuricemia and history or presence of gout,
    • • patients taking urate-lowering therapies,

    As part of the study, patients are under constant care of the attending physician, receive free treatment and have free full diagnostics included in the clinical trial. The patient receives reimbursement for travel costs for each visit.


    SUBMIT FOR THE TEST
  • add_boxPsoriatic Arthritis – conventional treatment
    Study description:

    Phase 3 study evaluating the efficacy and safety of deucravacitinib in patients with active psoriatic arthritis not treated with disease-modifying biologics.

    The main criteria that the patient must meet:
    • • age: at least 18 years old,
    • • diagnosis of PSA for at least 3 months,
    • • no response to conventional treatment.

    As part of the study, patients are under the constant care of the attending physician, receive free treatment and have free full diagnostics. The patient is reimbursed for travel expenses for each visit.


    SUBMIT FOR THE TEST
  • add_boxLower lumbar back pain
    Study description:

    Phase III study to prove the additional benefit of full-spectrum hemp extract VER-01 over opioids in the treatment of patients with chronic non-specific low back pain.

    Main criteria::
    • • age: at least 18 years old,
    • • chronic (at least 3 months) non-specific pain in the lower back,,
    • • ineffectiveness or intolerance of previous conventional treatment – non-opioid analgesics (including combinations).

    As part of the examination, the patient undergoes full diagnostics at each visit. The patient is also reimbursed for travel expenses for each visit.


    SUBMIT FOR THE TEST

  • add_boxCOPD
    Study description:

    Phase III study for patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis.

    Main criteria:
    • • age: at least 4o years old,
    • • diagnosis of COPD for at least 12 months with chronic bronchitis.

    As part of the study, patients have full diagnostics and spirometric tests.


    SUBMIT FOR THE TEST
  • add_boxDermatomyositis or polymyositis
    Study description:

    Phase III study to evaluate the effectiveness of the study drug in participants with active dermatomyositis or polymyositis.

    Main criteria:
    • • age: at least 18 years old,
    • • ddiagnosis of dermatomyositis or polymyositis.
    • • ineffectiveness of current treatment.

    As part of the study, patients are under constant care of the attending physician, receive free treatment and have free full diagnostics included in the clinical trial. The patient receives reimbursement for travel costs for each visit.


    SUBMIT FOR THE TEST
  • add_boxSystemic scleroderma
    Study description:

    Phase III study evaluating the efficacy, safety and tolerability of the study drug in the form of tablets for patients with generalized systemic sclerosis.

    Main criteria:
    • • aged between 18 and 75,
    • • documented diagnosis of systemic sclerosis,
    • • diagnosis of the disease no longer than 6 years from the onset of the first symptom,
    • • mRSS ≥15.

    As part of the study, patients are under the constant care of the attending physician, receive free treatment and have free full diagnostics (Spirometry, HRCT, echocardiography and DLCO test). The patient is reimbursed for travel expenses for each visit.


    SUBMIT FOR THE TEST
  • add_boxCardiological study for patients with high cardiovascular risk
    Study description:

    Phase III trial evaluating the effectiveness of PCSK9 in reducing major adverse cardiovascular events in participants at high cardiovascular risk.

    Main criteria:
    • • occurrence of serious atherosclerotic cardiovascular diseases,
    • • patient treated with a moderate or high intensity statin (±LLT without statin),
    • • patients taking a stable dose of all basic LLTs (including statins and non-statin-resistant drugs).

    As part of the study, patients are under constant care of the attending physician, receive free treatment and have free full diagnostics included in the clinical trial. The patient receives reimbursement for travel costs for each visit.


    SUBMIT FOR THE TEST
  • add_boxHidradenitis Suppurativa
    Study description:

    Phase III study to evaluate the effectiveness of isocibep for patients with moderate to severe acne inversa.

    Main criteria:
    • • age: at least 18 years old,
    • • diagnosis of HS occurring in two different parts of the body,
    • • ineffectiveness of current treatment.

    As part of the study, patients are under constant care of the attending physician, receive free treatment and have free full diagnostics included in the clinical trial. The patient receives reimbursement for travel costs for each visit.


    SUBMIT FOR THE TEST
  • add_boxAtopic Dermatitis
    Study description:

    Phase Ib study assessing, among others, safety and tolerability of two different doses of the drug tested in patients with atopic dermatitis.

    Main criteria:
    • • age: 18 to 75 years,
    • • diagnosed with moderate to severe atopic dermatitis at least 12 months before the first visit,
    • • a history of inadequate response to treatment with topical medications, unless topical treatment is medically inadvisable (e.g. due to side effects, safety risks and/or previous intolerance).

    As part of the study, patients are under constant care of the attending physician, receive free treatment and have free full diagnostics included in the clinical trial. The patient receives reimbursement for travel costs for each visit.


    SUBMIT FOR THE TEST
  • add_boxVitiligo
    Study description:

    Randomized, placebo-controlled, double-blind Phase 3 study evaluating the efficacy, safety, and tolerability of Upadacitinib in adults and adolescents with vitiligo.

    Main criteria:
    • • Adults and adolescents ≥ 12 years of age,
    • • Documented clinical diagnosis of NSV (nonsegmental vitiligo),
    • • The patient must have no history of active skin disease other than vitiligo that could interfere with the evaluation of vitiligo.

    As part of the study, patients are under constant care of the attending physician, receive free treatment and have free full diagnostics included in the clinical trial. The patient receives reimbursement for travel costs for each visit.


    SUBMIT FOR THE TEST

APPLICATION FORM


call
facebook
mail
PL